A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Dec 7, 2023
Trial Information
Current as of July 06, 2025
Recruiting
Keywords
ClinConnect Summary
The IMPART trial is studying how to improve the decision-making skills of people with stage 4 chronic kidney disease (CKD) and their caregivers. The goal is to help these patients and their caregivers work together better when making important medical decisions. By participating in this study, participants will receive training from coaches on how to support each other in decision-making. The study will involve about 64 pairs of patients and caregivers, and they will be randomly assigned to different training sessions to see which approach is most effective.
To be eligible for this trial, patients must be at least 18 years old, have a diagnosis of stage 4 CKD, and have a caregiver who can help them. Caregivers must also be at least 18 years old and be someone close to the patient who assists with medical decisions. Participants will be asked to complete some questionnaires and attend training sessions, but they will not receive dialysis or be in hospice care during the study. This trial is a great opportunity for patients and their caregivers to enhance their partnership in managing CKD together.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients
- • 1. Age ≥18;
- • 2. EMR documented diagnosis of stage 4 CKD (2 eGFR 29-15 within 90 days);
- • 3. Ability to speak and read English and complete baseline questionnaires;
- • 4. Patients must have an enrolled caregiver
- Exclusion Criteria:
- • Patients
- • 1. Receiving hospice;
- • 2. Receiving dialysis;
- • 3. Medical record documentation of active unmedicated severe mental illness, moderate-severe dementia, suicidal ideation, uncorrected hearing loss, and active substance abuse.
- Inclusion Criteria:
- • Caregivers
- • 1. Age ≥18;
- • 2. Self-endorsing or identified by the patient as a relative, friend, or partner that has a close relationship with you and who assists you with your medical decisions and who may or may not live in the same residence as you and who is not paid for their help
- • 3. Caring for a patient with CKD;
- • 4. Ability to speak and read English and complete baseline questionnaires;
- • 5. Caregivers must have an enrolled patient.
- Exclusion Criteria:
- • Caregivers 1) Self-reported unmedicated mental illness, Moderate-severe dementia, active suicidal ideation, uncorrected hearing loss, or active substance abuse ascertained by scripted study introduction questioning.
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Patients applied
Trial Officials
Shena Gazaway, PhD
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported